“The total prostate cancer treatment device market is expected to grow at double-digit rates over the forecast period, primarily driven by sales of robotic prostatectomy and EBRT capital equipment,” said Dr. Kamran Zamanian, CEO of iData. “Not only is the incidence of prostate cancer increasing but the procedure of robotic prostatectomy has been gaining acceptance by urologists, due to their clinical benefits over traditional methods.”

According to the report, external beam radiation therapy was the most popular procedure performed on patients diagnosed with prostate cancer in 2011, accounting for almost 80 percent of the total number of procedures performed that year. Robotic prostatectomy, however, grew at double-digit rates and is expected to continue to see strong growth through 2018. Within the prostate cancer treatment market, Intuitive Surgical monopolized robotic prostatectomy with its daVinci surgical system, while Varian Medical Systems and Siemens dominated the external beam radiation therapy market, and C.R. Bard dominated the brachytherapy market.

Additionally, the intermittent catheter market is set to continue its double-digit growth through 2018 with Coloplast, C.R. Bard and Covidien battling for control of this segment.

“The significant increase in intermittent catheter sales can be contributed to changes made by the Centers for Medicare and Medicaid Services for the reimbursement of intermittent urinary catheters, as well as the growing demand for hydrophilic-coated catheters,” said Zamanian. “These factors have caused the total urinary intermittent catheter market to grow significantly in the past year.”